Equities Analysts Offer Predictions for MLTX Q2 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright increased their Q2 2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research note issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.75) per share for the quarter, up from their prior estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.90) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.75) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.54) EPS.

A number of other equities analysts have also recently issued reports on the company. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Needham & Company LLC lifted their price objective on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Finally, Leerink Partners upped their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $24.21.

MoonLake Immunotherapeutics Stock Up 2.2%

Shares of MLTX opened at $19.36 on Wednesday. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The company has a 50-day moving average price of $18.94 and a two-hundred day moving average price of $17.65. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -5.00 and a beta of 1.04. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07).

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 50,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider owned 2,824,551 shares of the company’s stock, valued at approximately $54,881,025.93. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the sale, the chief executive officer owned 2,774,893 shares in the company, valued at $55,553,357.86. The trade was a 2.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 250,000 shares of company stock valued at $4,919,138. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in MoonLake Immunotherapeutics in the 2nd quarter valued at about $58,000. Avidity Partners Management LP acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth approximately $932,000. Bank of America Corp DE lifted its position in shares of MoonLake Immunotherapeutics by 5,255.8% during the first quarter. Bank of America Corp DE now owns 724,794 shares of the company’s stock worth $13,510,000 after purchasing an additional 711,261 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of MoonLake Immunotherapeutics by 64.7% during the first quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock valued at $64,304,000 after purchasing an additional 1,355,640 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of MoonLake Immunotherapeutics by 221.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock valued at $53,000 after purchasing an additional 1,974 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics News Roundup

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and $45 price target on MoonLake Immunotherapeutics, signaling continued analyst confidence in the stock. HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Positive Sentiment: The firm raised its FY2026 EPS estimate to a loss of $2.90 from $3.25, and also improved several quarterly forecasts, indicating a slightly better outlook for near-term profitability. Analyst estimate revisions
• Positive Sentiment: HC Wainwright lifted its FY2027 EPS estimate to a loss of $2.54 from $3.06, along with higher estimates for Q1 2027 and Q4 2027, reinforcing expectations for gradual improvement. Analyst estimate revisions
• Neutral Sentiment: The analyst updates were mixed across quarters, with some estimates raised and others lowered, so the move appears driven more by overall positive sentiment than by a single major catalyst.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.